Ava raises $30M Series B for its fertility-tracking bracelet
As the worlds of health and technology continue to knit closer together through advances in hardware and big data analytics, a startup called Ava, which has built a $199 wearable device and app to help women track their fertility cycles …
Context & Ripple Effects
Ava's $30M Series B extends a funding arc that began with software: Clue took an early $7M round to build a female-health platform in 2015 and followed with a $20M Series B in 2016, establishing period tracking as a venture-backable category. Ava's move is the hardware branch of that thesis — a $199 bracelet plus app rather than an app alone.
The bet has since been validated downstream: Flo Health's $200M+ Series C at a $1B+ valuation in 2024 showed subscription fertility apps can reach unicorn scale, while AiVF's $25M round for AI-driven IVF prediction pushed capital deeper into the treatment side of the funnel.
First-order effects
- Ava gets the capital to scale manufacturing and distribution of a $199 device whose value depends on sensor accuracy across cycles — a cost structure app-only rivals like Clue never had to carry.
- Clue and other period-tracking apps now face a competitor whose physiological data collection is harder to replicate than calendar-and-symptom logging.
Second-order effects
- App-only players are pushed toward their own hardware partnerships or richer data features to defend subscription pricing, since Ava's bracelet gives it a defensible signal advantage.
- Wearable investors gain a template beyond fitness: Cala Health's $50M Series C for disease-targeting wearables and Whoop's performance-tracking raises show generalist wearable capital migrating toward specific health outcomes, with women's health as one of the clearest use cases.
Third-order effects
- If the pattern holds, femtech consolidates around platforms that own both the sensor stream and the subscription relationship — Flo's billion-dollar outcome marks the ceiling, and hardware-backed entrants must either reach similar scale or become acquisition targets.
- Fertility tracking becomes the entry point to a longer care pathway — conception, pregnancy, IVF — pulling wearables companies toward regulated medical territory and closer ties with clinics like those AiVF serves.
The trend: Women's health tracking is shifting from free symptom-logging apps to sensor-backed hardware with proprietary physiological data, a category that has since produced billion-dollar subscription businesses.